Pulmonary cavitary disease due to Mycobacterium xenopi
Yousri Ben Abdallah, Nabil Belfeki, Timothée Klopfenstein, Souheil Zayet
Infectious Medicine · 2022-01
Abstract
Non-tuberculous mycobacteria are a significant cause of pulmonary infections worldwide and can be clinically challenging. Mycobacterium xenopi (M. xenopi) has a low pathogenicity and usually requires immunosuppression or lung diseases. We describe herein a scarce case of pulmonary cavitary disease attributed to M. xenopi in a 57-year-old Caucasian patient with underlying structural lung disease successfully treated with rifampicin, ethambutol, clarithromycin, and amikacin.
MeSH terms
- Ethambutol
- Medicine
- Rifampicin
- Amikacin
- Clarithromycin
- Immunosuppression
- Mycobacterium avium complex
- Lung
- Antimycobacterial
- Disease
- Tuberculosis
- Mycobacterium tuberculosis
- Internal medicine